NeuroRx, Inc. operates as a clinical stage-small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders. Its drug candidate includes Cyclurad, an oral therapeutic for the treatment of acute/elevated suicidal ideation/crisis in bipolar depression. The company was incorporated in 2015 and is headquartered in Wilmington, Delaware.